Pricing Log in Create free account
Friday 6 November 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

CORT Healthcare Biotechnology

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.

Revenue
+64.0%
EPS
+525.8%
Free cash flow
+161.0%

Quarter to September 2026, against a year earlier

72.63 1.00 +1.40%
Market cap
$7.8B
P/E
47.5×
Fwd P/E
39.8×
Dividend yield
—
F-score
4/9
Altman Z
14.11
Beneish M
−2.76
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Corcept Therapeutics Incorporated (CORT) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Corcept Therapeutics Incorporated (CORT) trades at a P/S ratio of 8.0×. Over the past ten years it has ranged from 3.8× (April 2020) to 22.6× (June 2015); the current reading is higher than 54% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 4.7× (38.40%)
FY2024 7.7× 48.57%
FY2023 5.2× (3.23%)
FY2022 5.4× (14.34%)
FY2021 6.3× (26.66%)
FY2020 8.5× 88.99%
FY2019 4.5× (26.39%)
FY2018 6.1× (52.59%)
FY2017 12.9× 29.27%
FY2016 10.0× (5.46%)

Quarterly newest first

Period P/S ratio Change
Sep 2026 12.8× 15.61%
Jun 2026 11.0× 101.48%
Mar 2026 5.5× 15.31%
Dec 2025 4.7× (59.12%)
43 more quarters

Against its own ten years

Low 3.8× High 22.6×
Ten-year median 7.6×
Current reading's percentile 59

P/S ratio against peers

Company P/S ratio
ABVX Abivax SA Sponsored ADR compare n/m
CORT Corcept Therapeutics Incorporated 8.0×
MDGL Madrigal Pharmaceuticals, Inc. compare 8.2×
ARWR Arrowhead Pharmaceuticals, Inc. compare 12.3×
KRYS Krystal Biotech, Inc. compare 18.9×
PTGX Protagonist Therapeutics, Inc. compare 31.7×
CYTK Cytokinetics, Incorporated compare 64.4×
PRAX Praxis Precision Medicines, Inc. compare 901×
SYRE Spyre Therapeutics, Inc. compare 8,160×
Biotechnology industry median 9.2×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on CORT